The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 79, 98-103
Abstract
No abstract availableKeywords
Funding Information
- Patient-Centered Outcomes Research Institute (CER-1602-34473)
This publication has 36 references indexed in Scilit:
- Prevalence of Kawasaki Disease in Young Adults With Suspected Myocardial IschemiaCirculation, 2012
- Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 casesPediatric Rheumatology, 2012
- Evaluation of Kawasaki Disease Risk-Scoring Systems for Intravenous Immunoglobulin ResistanceThe Journal of Pediatrics, 2011
- Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective StudyThe Journal of Pediatrics, 2011
- Associated Symptoms in the Ten Days Before Diagnosis of Kawasaki DiseaseThe Journal of Pediatrics, 2009
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Resistance to Intravenous Immunoglobulin in Children with Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Infliximab treatment for refractory Kawasaki syndromeThe Journal of Pediatrics, 2005
- A SAS Procedure Based on Mixture Models for Estimating Developmental TrajectoriesSociological Methods & Research, 2001
- Gamma globulin re-treatment in Kawasaki diseaseThe Journal of Pediatrics, 1993